Sangamo Therapeutics (SGMO) 8-K Sangamo Therapeutics Reports Fourth Quarter and Full Year 2018

Exhibit 99.1

Sangamo Therapeutics, Inc. Point Richmond Tech Center 501 Canal Boulevard Richmond, CA 94804 510-970-6000 | sangamo.com

SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018

FINANCIAL RESULTS

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Brisbane, California,February 28, 2019– Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2018 financial results and recent business highlights.

Recent Highlights

• ST-920 IND acceptance:The U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug application (IND) forST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Sangamo expects to initiate the Phase 1/2 clinical trial evaluatingST-920 later this year.

• WORLDSymposium presentations:At the WORLDSymposium earlier in February, Sangamo presented interim results from the Phase 1/2 CHAMPIONS and EMPOWERS studies evaluatingSB-913 andSB-318, zinc finger nuclease (ZFN)in vivo genome editing product candidates for the treatment of Mucopolysaccharidosis Type II (MPS II) and MPS I, respectively. Sangamo believes data from these two studies provide complementary evidence supportive of a favorable safety profile and of the activity of the ZFN in vivo genome editing approach used in bothSB-913 andSB-318.

• EVP of R&D appointment: Sangamo appointed Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development.

• Completion of acquisition of TxCell:In the fourth quarter of 2018, Sangamo completed the acquisition of TxCell, SA. The acquisition positions Sangamo as a leader in the development of CAR-Tregs, which the Company plans to evaluate for solid organ transplant rejection and for autoimmune diseases.

“The enrollment of patients last year into our five active clinical trials has laid the foundation for a steady flow of data readouts in 2019,” said Sandy Macrae, CEO of Sangamo. “In the remainder of the year, we anticipate providing important data that will help us understand the potential clinical benefit of our MPS I and MPS II programs, as well as clinical results and analyses from three clinical hematology assets for hemophilia A, hemophilia B and beta thalassemia. We also expect four additional programs to progress into clinical development, including our wholly owned gene therapy for Fabry disease and CAR-Treg therapy for the prevention of solid organ transplant rejection, as well as partnered programs in sickle cell disease and oncology being developed in collaboration with Sanofi and Kite, respectively. I’m excited for what lies ahead as we continue to push forward the development of our genomic medicines.”

Anticipated Milestones in 2019

In Vivo Genome Editing

• SB-913: Nine patients are enrolled in the CHAMPIONS Study evaluatingSB-913 for MPS II, including three patients who recently entered the study in the expanded high-dose cohort. In 2019, Sangamo expects to report longer-term safety and biochemical measurements, as well as analyses of liver biopsies and enzyme replacement therapy withdrawal experience.

• SB-318: Three patients are enrolled in the EMPOWERS Study evaluatingSB-318 for MPS I. In 2019, Sangamo expects to report longer-term safety and biochemical measurements, as well as analyses of liver biopsies and enzyme replacement therapy withdrawal experience.

• SB-FIX: One patient is currently enrolled in the FIXtendz Study evaluatingSB-FIX for hemophilia B. Sangamo expects to enroll a second subject in the study and later in 2019 to report data including safety and factor expression levels.

• Second-generation reagents forin vivogenome editing platform: Sangamo has developed second-generation albumin locus ZFN constructs for potential use in the ongoingin vivogenome editing development programs. The Company plans to initiate a clinical trial this year using these second-generation ZFNs that should enable a Phase 3 decision for the MPS II program in 2020.

Gene Therapy

• SB-525: Eight patients are enrolled in the Alta Study evaluatingSB-525 gene therapy for hemophilia A, being developed in collaboration with Pfizer. In 2019, Sangamo expects to report data including safety and factor expression levels, as well as information regarding factor replacement use and bleeding events.

• ST-920: In 2019, Sangamo anticipates activating sites for the Phase 1/2 clinical trial evaluatingST-920 gene therapy for the treatment of Fabry disease.

Ex Vivo Cell Therapy

• ST-400 and BIVV003:ST-400 and BIVV003 are gene-edited cell therapies being developed in collaboration with Sanofi for the treatment of beta thalassemia and sickle cell disease. Sangamo has enrolled two patients in the Thales Study evaluatingST-400 for the treatment of beta thalassemia and in 2019 expects to report initial safety and efficacy data including levels of fetal hemoglobin and total hemoglobin. BIVV003 is being evaluated for the treatment of sickle cell disease in the Phase 1/2PRECIZN-1 trial run by Sanofi.

• TX200: In 2019, Sangamo anticipates filing a clinical trial application in Europe for TX200, an autologous CAR-Treg cell therapy for the prevention of solid organ transplant rejection. The Company expects to activate clinical sites byyear-end.

• KITE-037: Kite, a Gilead Company, has announced the intention to file an IND forKITE-037, an allogeneic anti-CD19CAR-T cell therapy, in the latter half of 2019.

Fourth Quarter 2018 Financial Results

For the fourth quarter ended December 31, 2018, Sangamo reported a consolidated net loss of $18.7 million, or $0.18 per share, compared to a net loss of $13.1 million, or $0.15 per share, for the same period in 2017. As of December 31, 2018, the Company had cash, cash equivalents, marketable securities and interest receivable of $400.5 million.

Revenues for the fourth quarter ended December 31, 2018 were $26.8 million, compared to $13.1 million for the same period in 2017. The increase came primarily from approximately $11.5 million in revenues related to the collaboration agreements with Pfizer for hemophilia A, and $9.0 million in revenues related to the collaboration with Kite, a Gilead Company, which included reimbursement of $2.7 million in research services. Fourth quarter 2018 revenues were primarily generated from Sangamo’s collaboration agreements with Pfizer, Kite, Sanofi, and Dow Agrosciences.

Total operating expenses for the fourth quarter ended December 31, 2018 were $47.6 million, compared to $26.8 million for the same period in 2017. Research and development expenses were $33.3 million for the fourth quarter of 2018, compared to $19.4 million for the same period in 2017. The increase was primarily due to manufacturing and clinical trial expenses related to the progress of the Company’s clinical development programs. General and administrative expenses were $14.4 million for the fourth quarter of 2018, compared to $7.5 million for the same period in 2017. This increase was primarily due to increased headcount in general support of growth for the Company’s pipeline and clinical programs.

Full Year 2018 Results

For the year ended December 31, 2018, the consolidated net loss was $68.3 million, or $0.70 per share, compared to a consolidated net loss of $54.6 million, or $0.70 per share, for the year ended December 31, 2017. Revenues were $84.5 million for the year ended December 31, 2018, compared to $36.6 million for the same period in 2017. The increase in revenues was primarily related to our collaboration and license agreements with Kite and Pfizer. Total operating expenses were $161.6 million for the year ended December 31, 2018, compared to $92.9 million for the same period in 2017. The increase in operating expenses was primarily related to overall Company growth and manufacturing and R&D expenses related to the advancement of Sangamo’s therapeutic pipeline.

Financial Guidance for 2019

• Operating Expense: Sangamo expects operating expense of $210 to 220 million for the year ending December 31, 2019.

• Cash and Investments: Sangamo projects that current cash, cash equivalents, marketable securities and interest receivable position should last at least two years.

Conference Call

Sangamo will host a conference call today, February 28, 2019, at 5:00 p.m. Eastern Time, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section underEvents and Presentations.

The conference calldial-in numbers are (877)377-7553 for domestic callers and (678)894-3968 for international callers. The conference ID number for the call is 6875578. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 28, 2019 to 11:59 p.m. ET on March 7, 2019. The conference call replay numbers for domestic and international callers are (855)859-2056 and (404)537-3406, respectively. The conference ID number for the replay is 6875578.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visitwww.sangamo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements regarding the initiation of clinical trials and activation of clinical trial sites in 2019, the expected disease targets for our product candidates, the presentation of clinical trial data from clinical trials in 2019, enrollment expectations in 2019, the filing of a clinical trial application in the European Union, and Sangamo’s 2019 financial guidance related to cash, cash equivalents, marketable securities and interest receivable and operating expense. These statements are not guarantees of future

performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation, enrollment and completion of clinical trials, whether the final results from a study will validate and support interim safety and efficacy data, Sangamo’s reliance on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s operations and business environments. These risks and uncertainties are described more fully in Sangamo’s Quarterly Report on Form10-Q for the quarter ended September 30, 2018 as filed with the Securities and Exchange Commission and Sangamo’s Annual Report on Form10-K that it intends to file this week. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Contact

Sangamo Therapeutics, Inc.

Investors:

McDavid Stilwell

510-970-6000, x219

mstilwell@sangamo.com

Varant Shirvanian

510-970-6000 x205

vshirvanian@sangamo.com

Media:

Aron Feingold

510-970-6000, x421

afeingold@sangamo.com

-more-

SELECTED CONSOLIDATED FINANCIAL DATA

(unaudited; in thousands, except per share data)

Statement of Operations Data:

	Three months ended December 31,						For the Year Ended December 31,
	2018			2017			2018			2017
Revenues:
Collaboration agreements	$	26,687		$	12,918		$	84,065		$	35,960
Research grants		150			159			387			607
Total revenues		26,837			13,077			84,452			36,567
Operating expenses:
Research and development		33,254			19,377			114,866			65,728
General and administrative		14,355			7,466			46,736			27,200
Total operating expenses		47,609			26,843			161,602			92,928
Loss from operations		(20,772	)		(13,766	)		(77,150	)		(56,361	)
Interest and other income, net		1,553			675			8,261			1,793
Net loss		(19,219	)		(13,091	)		(68,889	)		(54,568	)
Net loss attributable tonon-controlling interest		(555	)		—			(555	)		—
Net loss attributable to Sangamo Therapeutics, Inc. stockholders	$	(18,664	)	$	(13,091	)	$	(68,334	)	$	(54,568	)
Basic and diluted net loss per common share	$	(0.18	)	$	(0.15	)	$	(0.70	)	$	(0.70	)
Shares used in computing basic and diluted net loss per common share		102,057			84,820			96,941			78,084
SELECTED BALANCE SHEET DATA
	Year Ended December 31,
	2018			2017
	(in thousands)
Cash, cash equivalents, marketable securities and interest receivable	$	400,508		$	244,560
Total assets		590,395			286,741
Total stockholders’ equity		366,518			187,900

###